Instruction for use: Tactivin

Dosage form: Solution for subcutaneous administration; Substance-powder

Active substance: Thymus extract

ATX

L03AA Colony-stimulating factors

Pharmacological group:

Other immunomodulators

The nosological classification (ICD-10)

C80 Malignant neoplasm without specification of localization: Malignant tumor; Malignant neoplasm; Malignant neoplasms of different localization; Malignant tumors; Eton-Lambert syndrome; Locally prevalent forms of malignant neoplasms; Metastatic ascites; Metastatic ascites; Cerebellar degeneration in tumors; Hereditary cancers; Metastatic tumors; Cancer ascites; Solid tumors

C81 Hodgkin's disease [lymphogranulomatosis]: Paltauf-Sternberg disease; The generalized form of Hodgkin's disease; Lymphogranulomatosis; Hodgkin's disease; Hodgkin's lymphoma; Hodgkin's malignant lymphoma; Hodgkin's lymphoma; Lymphoproliferative diseases; Reticulosis fibromyaloid; Pelya-Ebstein fever

C91 Lymphoid leukemia [lymphatic leukemia]: Lymphatic leukemia; Lymphoproliferative diseases; Neuroleukemia; Refractory acute lymphoblastic leukemia; Refractory lymphoblastic leukemia; Transformation of preleukemias; Chronic lymphocytic leukemia; Lymphoproliferative disorders

D83.1 General variable immunodeficiency with predominance of immunoregulatory T-cell disorders: T-lymphocyte deficiency syndrome

Composition and release form

Solution for subcutaneous injection 1 amp.

Tactivine 0.1 g

Sodium chloride 8.85 g

Excipients: water for injection - up to 1 liter

In ampoules of 1 ml, complete with a knife ampoule; In a pack of cardboard 5 and 10 ampoules.

Description of dosage form

Colorless transparent liquid, odorless.

Characteristic

The preparation is of a polypeptide nature in the form of a ready-made solution for injections.

Pharmachologic effect

Mode of action - immunomodulatory.

Pharmacodynamics

It is an immunostimulating agent. In immunodeficient conditions, the drug normalizes the quantitative and functional indices of immunity, stimulates the production of lymphokines, incl. Α- and γ-interferon, restores the activity of T-killers, the functional activity of stem hemopoietic cells, and normalizes a number of other indices characterizing the intensity of immunity. Activates the macrophage system.

Indication of the drug Tactivin

Immunodeficiency states in adults and children (from 6 months to 14 years), arising from diseases such as:

Infectious purulent and septic processes;

Lymphoproliferative diseases (lymphogranulomatosis, lymphocytic leukemia);

Malignant neoplasms;

Persistent violations of the function of the thymus (radiation sickness, tumors of the thymus, operative removal of the thymus);

multiple sclerosis;

tuberculosis;

Recurrent ophthalmoherpes;

psoriasis;

shingles;

Dermatitis and dermatosis;

Frequently recurring ARVI, ARI;

Urological diseases of infectious etiology;

Lung diseases;

Chronic viral hepatitis;

Surgical interventions (in preoperative and postoperative periods);

Thymomegaly.

Contraindications

pregnancy;

The period of breastfeeding.

Side effects

Allergic reactions.

Dosing and Administration

SC, adults - 1 ml of 0.01% solution (which is 40 mcg / m2 or 1-2 mcg / kg) is administered at night, once a day, daily for 5-14 days. If necessary, the course of treatment is continued for 1 month to 2 ml every third day.

With persistent impairments of immunity Tactivin is prescribed for 5-14 days for 2 ml daily, and then 2 times a week for 2 ml for 6 months. Repeated courses of treatment are prescribed according to the indicators of immune status.

With multiple sclerosis, the drug is used daily for 1 ml for 5 days, then for 2 ml 2 times a week for life.

In severe cases of multiple sclerosis, Tactivin is prescribed in complex therapy with GCS (at the stage of SCS application once a day). The basic preparation is administered in the morning, and Tactivin - in the evening time of 1 ml, observing the interval between the administration of GCS and Tactinol 10-12 h.

For the treatment of surgical patients Tactivin is administered before the operation of 1 ml for 2 days and after it - for 5-14 days.

With malignant tumors, Tactivin is prescribed 5-6-day courses of 1 ml in intervals between courses of basic therapy.

For the treatment of recurrent ophthalmoherpes, 0.1 ml of conjunctival drug is administered, which is 4 μg / m2 or 0.1-0.2 μg / kg / day at intervals of 1 day for 4-5 days, or 1 ml of SC Within 7-10 days.

In herpes zoster inject 1 ml of Tactivin daily 7-10 days.

The course of treatment can be repeated after 2-3 weeks.

With hepatitis of various etiologies, Tactivin is prescribed for 2-3 ml daily for 10-12 days in combination with the basic preparations. The course of immunocorrection is repeated after 7 days.

Children from 6 months to 14 years of age, the drug is prescribed SC at a rate of 2-3 μg per 1 kg of body weight.

With frequent diseases of acute respiratory viral infection, acute respiratory infections, purulent-septic infections, with atopic dermatitis complicated with herpesvirus, Tactivin is administered daily for 7-10 days in combination with the basic preparations. Subsequent administration of the drug - 1 injection every other day for 1-2 weeks.

In malignant neoplasms and hepatitis in children, the treatment regimen does not differ from the treatment regimen in adults.

It is recommended to enter in the evening between 17 and 20 hours.

Storage conditions of the drug Tactivin

In the dark place at a temperature of 2-7 ° C.

Keep out of the reach of children.

Shelf life of the drug Tactivin

3 years.

Do not use after the expiry date printed on the package.